跳转至内容
Merck
CN

917710

Sigma-Aldrich

A1V1PF2-OEt

≥95%

别名:

AVP ligand, Ethyl (S)-2-((S)-1-((S)-2-((S)-2-aminopropanamido)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-3-(4-fluorophenyl)propanoate, IAP E3 ligase lead for protein degrader research, SNIPER building block

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H37FN4O5
分子量:
492.58
UNSPSC代码:
41116105
NACRES:
NA.22

ligand

A1V1PF2

质量水平

检测方案

≥95%

形式

powder

反应适用性

reagent type: ligand

官能团

amine

储存温度

2-8°C

SMILES字符串

N[C@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(OCC)=O)CC2=CC=C(C=C2)F)=O)=O)C(C)(C)C)=O)C

应用

A1V1PF2-OEt is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlight. An N-terminal variant of A1V1PF2-OEt is also available as BocA1V1PF2 (917478).

A1V1PF2-OEt conjugates are also available for degrader synthesis. Browse our full synthesis offering here: Browse our full synthesis offering here for streamlining SNIPER and PROTAC® degrader libraries: Degrader Building Blocks

917427 A1V1PF2-OEt-C6-NH2 hydrochloride
917672 A1V1PF2-OEt-C10-NH2 hydrochloride
917923 A1V1PF2-OEt-PEG1-NH2 hydrochloride
916676 A1V1PF2-OEt-PEG3-NH2 hydrochloride

Technology Spotlight: Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

法律信息

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

相关产品

产品编号
说明
价格

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies

商品

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门